References
External links

Bed bug on the University of Florida/IFAS Featured Creatures Web site
National Geographic segment on Bed bugs on YouTube
Bed bugs – University of Sydney and Westmead Hospital Department of Medical Entomology
Understanding and Controlling Bed Bugs – National Pesticide Information Center
CISR: Center for Invasive Species Research More information on Bed Bugs, with many photos and video
EPA bedbugs information page
A Code of Practice for the Control of Bed Bugs in Australia, ICPMR & AEPMA, Sydney Australia, September 2011. ISBN 1-74080-135-0. "Bed Bug Home Page". Bedbug.org.au. 14 October 2005. Retrieved 11 November 2013.
Pegcetacoplan, sold under the brand name Empaveli among others, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH).The most common side effects include injection-site reactions, infections, diarrhea, abdominal pain, respiratory tract infection, viral infection, and fatigue.Paroxysmal nocturnal hemoglobinuria is characterized by red blood cell destruction, anemia (red blood cells unable to carry enough oxygen to tissues), blood clots, and impaired bone marrow function (not making enough blood cells).Pegcetacoplan is the first treatment for paroxysmal nocturnal hemoglobinuria that binds to and inhibits complement protein C3. Pegcetacoplan was approved for medical use in the United States in May 2021. Pegcetacoplan binds to complement protein C3 and its activation fragment C3b with high affinity, thereby regulating the cleavage of C3 and the generation of downstream effectors of complement activation. Medical uses
Pegcetacoplan is indicated to treat adults with paroxysmal nocturnal hemoglobinuria (PNH). Pegcetacoplan is only available for patients who are under the special REMS program. Two weeks before receiving pegcetacoplan, patients must receive vaccinations for pneumonia, meningitis, or influenza type B. Patients who have been vaccinated in the past may still need to get vaccinated two weeks before initiation of the medication. Pharmacology
Patients with PNH have greater and uninhibited complement activity, which may leads to intravascular (inside blood vessels) or extravascular (within the liver or spleen) hemolysis. Adverse effects
Meningococcal (a type of bacteria) infections can occur in people taking pegcetacoplan and can become life-threatening or fatal if not treated early. Pegcetacoplan may also predispose individuals to serious infections, especially infections caused by encapsulated bacteria.